Katelyn Sanner Dixon

Dr. Katelyn Sanner Dixon

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2023 in Journal of Surgical Education
Verified
Journal Article
Closed access
SASarah E. Adkins
Sarah E. Adkins
KDKatelyn Sanner Dixon
Katelyn Sanner Dixon
HMHeather M. Minchew
Heather M. Minchew
DVDylan Vance
Dylan Vance
JBJalee Birney
Jalee Birney
Lyndsey KilgoreLyndsey Kilgore
Lyndsey Kilgore

2 November 2024 in The American Journal of Surgery
Verified
Journal Article
Closed access
SASarah E. Adkins
Sarah E. Adkins
DVDylan T. Vance
Dylan T. Vance
KDKatelyn Sanner Dixon
Katelyn Sanner Dixon
JBJalee Birney
Jalee Birney
JLJoshua Lawton
Joshua Lawton
Lyndsey KilgoreLyndsey Kilgore
Lyndsey Kilgore

31 August 2024 in Journal of Surgical Education
Verified
Journal Article
Closed access
KDKatelyn Sanner Dixon
Katelyn Sanner Dixon
ARAmani Raheel
Amani Raheel
SASarah Adkins
Sarah Adkins
BJBraden M. Johnson
Braden M. Johnson
JAJack M. Ayres
Jack M. Ayres
Lyndsey KilgoreLyndsey Kilgore
Lyndsey Kilgore

19 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CHCorey Hounschell
Corey Hounschell
ASAubrey C. Swilling
Aubrey C. Swilling
SMSahaam Mirza
Sahaam Mirza
KDKatelyn Sanner Dixon
Katelyn Sanner Dixon
JHJill Haley
Jill Haley
MAMazin F. Al-Kasspooles
Mazin F. Al-Kasspooles
Background/Objectives: Peritoneal surface metastases (PSMs) from colorectal cancer have high rates of peritoneal recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Prior studies dichotomize peritoneal recurrence into “early” and “late,” limiting insight into how clinicopathologic factors influence recurrence timing. This study aimed to identify predictors of peritoneal recurrence and quantify their continuous association with time to recurrence following CRS/HIPEC. Methods: Patients undergoing CC-0 CRS/HIPEC for colorectal PSM from 2018 to 2024 were identified from a prospectively maintained database. The primary outcome was peritoneal surface recurrence. Variables included peritoneal cancer index (PCI), tumor location, histology, HIPEC regimen, and KRAS/BRAF/SMAD4 status. Factors with p < 0.10 on univariable analysis were entered into multivariable logistic regression (recurrence: yes/no) and linear regression (time to recurrence). Results: Among 133 patients, 64 (48.1%) developed peritoneal recurrence. Median time to recurrence was 41.4 weeks (IQR 24.9–74.0), and PCI was higher among those who recurred (median 11.0 vs. 5.0, p < 0.01). Neither tumor stage, histology, intraperitoneal chemotherapy agent, nor molecular alterations were associated with increased risk of peritoneal recurrence. When controlling for PCI, right- and sigmoid-colon primaries independently predicted peritoneal recurrence compared to all other locations without influence on recurrence timing (right: OR 7.18; sigmoid: OR 6.54; p < 0.01). Among patients who recurred, each one-point increase in PCI corresponded to a 2.43-week earlier relapse (p < 0.01). Conclusions: Nearly half of patients with colorectal PSM recurred despite complete CRS/HIPEC. Tumor location predicted peritoneal recurrence, while PCI independently shortened time to relapse. Modeling PCI as a continuous predictor refines postoperative risk stratification and may inform individualized surveillance strategies.